Blinded by the light: the growing complexity of p53
For many people, non-GLP-1 medications, alone or in combination, can produce meaningful, sustainable results when chosen thoughtfully
Efficacy endpoints include changes in abdominal subcutaneous fat volume (measured by MRI) and changes in body weight
For a more detailed research summary with study citations, see our complete retatrutide research guide, our Australian retatrutide guide, our clinical trial side-effects analysis, and our dosing and titration protocol research guide
Additionally, GLP-1s decrease appetite
Similarly, Mounjaro is usually covered for diabetes, while Zepbound may or may not be covered for weight management depending on the plan